Inogen (INGN) to Release Earnings on Thursday

Inogen (NASDAQ:INGN) is expected to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Inogen to announce earnings of ($0.17) per share and revenue of $95.2330 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Inogen (NASDAQ:INGN) last posted its earnings results on Thursday, May 7th. The medical technology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.06). Inogen had a negative net margin of 7.08% and a negative return on equity of 12.90%. The business had revenue of $85.11 million for the quarter, compared to analyst estimates of $82.35 million. On average, analysts expect Inogen to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Inogen Price Performance

NASDAQ:INGN traded up $0.07 during mid-day trading on Tuesday, hitting $6.79. The company’s stock had a trading volume of 60,199 shares, compared to its average volume of 289,053. The business’s fifty day moving average is $6.47 and its two-hundred day moving average is $6.38. The stock has a market cap of $183.70 million, a price-to-earnings ratio of -7.45 and a beta of 1.58. Inogen has a 1 year low of $5.34 and a 1 year high of $9.13.

Insiders Place Their Bets

In other Inogen news, EVP Boyer Jennifer M. Yi sold 10,938 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $6.60, for a total value of $72,190.80. Following the completion of the transaction, the executive vice president owned 5,039 shares in the company, valued at approximately $33,257.40. This represents a 68.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Inogen

Institutional investors and hedge funds have recently modified their holdings of the business. Alliancebernstein L.P. boosted its holdings in Inogen by 3.9% during the 3rd quarter. Alliancebernstein L.P. now owns 51,120 shares of the medical technology company’s stock valued at $418,000 after acquiring an additional 1,900 shares during the period. Russell Investments Group Ltd. grew its position in Inogen by 14.6% in the 4th quarter. Russell Investments Group Ltd. now owns 19,543 shares of the medical technology company’s stock valued at $131,000 after acquiring an additional 2,487 shares in the last quarter. Rhumbline Advisers increased its stake in Inogen by 7.0% during the second quarter. Rhumbline Advisers now owns 39,059 shares of the medical technology company’s stock worth $275,000 after purchasing an additional 2,561 shares during the period. American Century Companies Inc. increased its stake in Inogen by 4.9% during the second quarter. American Century Companies Inc. now owns 61,238 shares of the medical technology company’s stock worth $431,000 after purchasing an additional 2,858 shares during the period. Finally, Barclays PLC lifted its position in shares of Inogen by 4.5% during the fourth quarter. Barclays PLC now owns 81,980 shares of the medical technology company’s stock worth $551,000 after purchasing an additional 3,515 shares in the last quarter. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Analyst Upgrades and Downgrades

INGN has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a report on Friday, May 8th. Freedom Capital raised Inogen to a “strong-buy” rating in a report on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

About Inogen

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.